Publication: Genetically engineered T cells to target EGFRvIII expressing glioblastoma
No Thumbnail Available
Open/View Files
Date
2009
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Springer Verlag
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Bullain, Szofia S., Ayguen Sahin, Oszkar Szentirmai, Carlos Sanchez, Ning Lin, Elizabeth Baratta, Peter Waterman, Ralph Weissleder, Richard C. Mulligan, and Bob S. Carter. 2009. “Genetically Engineered T Cells to Target EGFRvIII Expressing Glioblastoma.” Journal of Neuro-Oncology 94 (3): 373–82. https://doi.org/10.1007/s11060-009-9889-1.
Research Data
Abstract
Glioblastoma remains a significant therapeutic challenge, warranting further investigation of novel therapies. We describe an immunotherapeutic strategy to treat glioblastoma based on adoptive transfer of genetically modified T-lymphocytes (T cells) redirected to kill EGFRvIII expressing gliomas. We constructed a chimeric immune receptor (CIR) specific to EGFRvIII, (MR1-zeta). After in vitro selection and expansion, MR1-zeta genetically modified primary human T-cells specifically recognized EGFRvIII-positive tumor cells as demonstrated by IFN-gamma secretion and efficient tumor lysis compared to control CIRs defective in EGFRvIII binding (MRB-zeta) or signaling (MR1-del zeta). MR1-zeta expressing T cells also inhibited EGFRvIII-positive tumor growth in vivo in a xenografted mouse model. Successful targeting of EGFRvIII-positive tumors via adoptive transfer of genetically modified T cells may represent a new immunotherapy strategy with great potential for clinical applications.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service